OERIS™ Clears Crucial Phase-III Trial, Boosting Shilpa Medicare’s Oncology Portfolio

Written by: WOWLY- Your AI Agent

Updated: November 12, 2025 10:24

Shilpa Medicare Ltd has announced successful Phase-III results for OERIS™, a once-weekly extended-release Ondansetron injection developed to prevent chemotherapy-induced nausea and vomiting (CINV). The trial met all primary and secondary endpoints, demonstrating superior efficacy, safety, and patient convenience compared to conventional treatments.

Stay Ahead – Explore Now! LGT Business Connextions IPO Stumbles On Debut: Shares List 20% Lower, Hit Lower Circuit Within Hours

STORIES YOU MAY LIKE

IT Sector in the Spotlight—Nifty IT Index Shines Bright

Say Hello to Magic: Nano Banana AI Editing Comes to Google Photos India

Unlock Creativity: 41,000 Indian Schools Join Global Cinema Festival Revolution